Acarix CADScor®System for early rule-out of Coronary Artery Disease (CAD) gains traction from established German users.


Acarix AB (publ) (“Acarix”), today reported positive feedback from German users of its handheld CADScor®System for ruling out CAD. Germany is an important market and Acarix offers a reimbursement code for private patients and is continuing the reimbursement process for statutory health insurance patients with the aim of providing physicians with more opportunities to use the CADScor®System for their patients.


About Acarix
Acarix is a Swedish medical device company that innovates solutions for rapid AI-based rule out of Coronary Artery Disease (CAD). The CE approved and FDA DeNovo cleared Acarix CADScor®System is intended for patients experiencing chest pain with suspected CAD and designed to help reduce millions of unnecessary, invasive and costly diagnostic procedures. The CADScor system calculates a patient-specific CAD-score non-invasively in less than10 minutes and can help rule out more than one third of patients with at least 96% certainty of not being sick (in a population with approx. 10% CAD prevalence). Acarix is listed on the Nasdaq First North Premier Growth Market (ticker: ACARIX). Redeye AB (+46 (0)8 121 576 90, is Certified Advisor of Acarix.

For more information, please visit